Home / People / Fionnuala Rice
Portrait of Fionnuala Rice

Fionnuala Rice

Senior Associate

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Fionnuala is a Senior Associate in the Intellectual Property department.

more less


  • 2016 – Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford
  • 2010 – Legal Practice Course, BPP Law School, London
  • 2009 – Graduate Diploma in Law, Oxford Brookes University
  • 2008 – BA (Hons) Physiological Sciences, University of Oxford
more less
Get in contact with


29 October 2020
EU Gen­er­al Court cla­ri­fies in­ter­pret­a­tion of “sat­is­fact­ory meth­od” in the...
In the re­cent case of Me­dac Gesell­schaft für klin­is­che Spezi­al­prä­par­ate mbH v European Com­mis­sion, the EU Gen­er­al Court has an­nulled a de­cision of the European Com­mis­sion in which it held that the ap­plic­ant’s...
18 June 2020
MHRA re­leases up­dated guid­ance on med­ic­al device soft­ware and apps
On 4 June 2020, the Medi­cines and Health­care products Reg­u­lat­ory Agency (“MHRA”) pub­lished its up­dated guid­ance on med­ic­al device stand-alone soft­ware, which is in­ten­ded to cla­ri­fy the types of soft­ware...
06 March 2020
MDR - Agree­ments with third party con­tract man­u­fac­tur­ers
The EU Med­ic­al Device Reg­u­la­tion, which comes in­to force on 26 May 2020, will lead not only to big changes in how med­ic­al devices are reg­u­lated, but also to more thought be­ing giv­en to agree­ments between...
07 February 2020
MHRA up­dates guid­ance on with­draw­al of no­ti­fied body ser­vices (UK)
The Medi­cines and Health­care products Reg­u­lat­ory Agency (MHRA) has re­cently is­sued guid­ance for situ­ations where a no­ti­fied body with­draws all, or part, of its ser­vices in re­la­tion to med­ic­al devices...
13 December 2018
Di­git­al Health - The new reg­u­la­tion of med­ic­al soft­ware and apps
The new Med­ic­al Devices Reg­u­la­tion 2017/745 (“MDR”), which comes in­to force in May 2020, rep­res­ents a huge over­haul of the reg­u­lat­ory frame­work gov­ern­ing med­ic­al devices in the EU.  The com­pli­ance...
15 August 2018
New MHRA guid­ance on Brexit im­ple­ment­a­tion peri­od and the lifes­ci­ences...
On 6 Au­gust 2018, the MHRA re­leased new guid­ance on what the Brexit im­ple­ment­a­tion peri­od means for the lifes­ci­ences sec­tor, as well as an up­date on the ap­plic­a­tion of the new EU Clin­ic­al Tri­als Reg­u­la­tion...
3 August 2018
CMS ad­vises lead­ing In­ter­net-of-Things pro­vider Arkessa in deal with ECI...
In­ter­na­tion­al law firm CMS has ad­vised on the man­age­ment buy­out of Arkessa, the lead­ing In­ter­net-of-Things (“IoT”) man­aged ser­vices pro­vider, to private equity firm ECI Part­ners. Arkessa en­ables en­ter­prises...
24 April 2018
Shire v EMA: Cla­ri­fic­a­tion on orphan des­ig­na­tion for products with the...
On 22 March 2018 the EU Gen­er­al Court handed down its judg­ment in Case T-80/16 Shire Phar­ma­ceut­ic­als Ire­land Ltd v European Medi­cines Agency (EMA). The case centred around wheth­er a new medi­cin­al product...